Hye Na Kim
Overview
Explore the profile of Hye Na Kim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
314
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wilkes M, Shibuya A, Liu Y, Mark K, Mercado J, Saxena M, et al.
J Biol Chem
. 2024 Jul;
300(8):107542.
PMID: 38992436
Diamond Blackfan Anemia (DBA) is a rare macrocytic red blood cell aplasia that usually presents within the first year of life. The vast majority of patients carry a mutation in...
2.
Ly C, Ogana H, Kim H, Hurwitz S, Deeds E, Kim Y, et al.
Integr Biol (Camb)
. 2023 May;
15.
PMID: 37247849
The recurrence of cancer following chemotherapy treatment is a major cause of death across solid and hematologic cancers. In B-cell acute lymphoblastic leukemia (B-ALL), relapse after initial chemotherapy treatment leads...
3.
Kim H, Ogana H, Sanchez V, Nichols C, Kim Y
Curr Top Microbiol Immunol
. 2022 Oct;
436:393-407.
PMID: 36243854
Despite the therapeutic progress, relapse remains a major problem in the treatment of acute lymphoblastic leukemia (ALL). Most leukemia cells that survive chemotherapy are found in the bone marrow (BM),...
4.
Ruan Y, Kim H, Ogana H, Gang E, Li S, Liu H, et al.
Exp Ther Med
. 2021 Dec;
23(1):47.
PMID: 34934426
Treatment of resistant or recurrent acute lymphoblastic leukemia (ALL) remains a challenge. It was previously demonstrated that the adhesion molecule integrin α4, referred to hereafter as α4, mediates the cell...
5.
Ruan Y, Kim H, Ogana H, Wan Z, Hurwitz S, Nichols C, et al.
Front Oncol
. 2021 Dec;
11:766888.
PMID: 34926269
The PI3K/Akt pathway-and in particular PI3Kδ-is known for its role in drug resistant B-cell acute lymphoblastic leukemia (B-ALL) and it is often upregulated in refractory or relapsed B-ALL. Myc proteins...
6.
Schonthal A, Swenson S, Minea R, Kim H, Cho H, Mohseni N, et al.
Cancers (Basel)
. 2021 Jul;
13(14).
PMID: 34298603
Despite progress in the treatment of acute myeloid leukemia (AML), the clinical outcome remains suboptimal and many patients are still dying from this disease. First-line treatment consists of chemotherapy, which...
7.
Kim H, Ruan Y, Ogana H, Kim Y
Front Oncol
. 2021 Jan;
10:592733.
PMID: 33425742
The interaction between leukemia cells and the bone microenvironment is known to provide drug resistance in leukemia cells. This phenomenon, called cell adhesion-mediated drug resistance (CAM-DR), has been demonstrated in...
8.
Ruan Y, Ogana H, Gang E, Kim H, Kim Y
Adv Exp Med Biol
. 2020 Oct;
1270:107-121.
PMID: 33123996
Dysregulated Wnt signaling plays a central role in initiation, progression, and metastasis in many types of human cancers. Cancer development and resistance to conventional cancer therapies are highly associated with...
9.
Ruan Y, Kim H, Ogana H, Kim Y
Int J Mol Sci
. 2020 Sep;
21(17).
PMID: 32872365
Leukemia is an aggressive hematologic neoplastic disease. Therapy-resistant leukemic stem cells (LSCs) may contribute to the relapse of the disease. LSCs are thought to be protected in the leukemia microenvironment,...
10.
Liu H, Gang E, Kim H, Ruan Y, Ogana H, Wan Z, et al.
Cells
. 2020 Jun;
9(6).
PMID: 32560076
Drug resistance is an obstacle in the therapy of acute lymphoblastic leukemia (ALL). Whether the physical properties such as the motility of the cells contribute to the survival of ALL...